Post

New research · Ophthalmology
Oncology research · 16h
ReviewOncology research · 2026

Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art.

Stefano Dore, Matteo Sacchi, Antonio Pinna … Panagiotis Paliogiannis
Read paper
OphthalmologyReview

Uveal melanoma accounts for 80% of all noncutaneous melanoma cases.

Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art.

Stefano Dore … Panagiotis Paliogiannis
Oncology research · 2026
Background

Uveal melanoma (uveal melanoma) is the most common intraocular cancer, with approximately 5.2 individuals per million affected annually in the United States.

Purpose

This review aims to present the latest advances in the clinical molecular pathology of uveal melanoma, along with the resulting targeted, immunological, and other therapies that have been introduced or are currently under investigation.

80%
Results
80%
uveal melanoma makes up most noncutaneous melanoma cases, far more than other types
More results

Clinically, it remains silent in about 30% of the cases; when symptomatic, it generally causes metamorphopsia (painless loss or distortion of vision) and/or photopsia (flashing or flickering of light in the visual field).

Discoloration of the iris, astigmatism, glaucoma, and even blindness are other, less common clinical manifestations.

More results

Several pathophysiological mechanisms underlie the development of uveal melanoma.

Chromosomal aberrations, inflammatory and immunological alterations are often concurrent factors for the development and progression of uveal melanoma.

“
Conclusion

This review aims to present the latest advances in the clinical molecular pathology of uveal melanoma, along with the resulting targeted, immunological, and other therapies that have been introduced or are currently under investigation.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving